|
|
Volumn 46, Issue 6, 2007, Pages 1035-1036
|
|
Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-α agents: The Newcastle (UK) experience [2]
a,b,c
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BCG VACCINE;
CORTICOSTEROID;
DISEASE MODIFYING ANTIRHEUMATIC DRUG;
ETANERCEPT;
GAMMA INTERFERON;
GOLD;
INFLIXIMAB;
METHOTREXATE;
TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
ADULT;
AGED;
BCG VACCINATION;
BLOOD ANALYSIS;
BLOOD SAMPLING;
CHEMOPROPHYLAXIS;
CLINICAL EFFECTIVENESS;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
DIAGNOSTIC ACCURACY;
DIAGNOSTIC VALUE;
FALSE POSITIVE RESULT;
FEASIBILITY STUDY;
FEMALE;
HUMAN;
LETTER;
MAJOR CLINICAL STUDY;
MALE;
MEDICAL AUDIT;
MYCOBACTERIOSIS;
MYCOBACTERIUM TUBERCULOSIS;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SCREENING TEST;
SENSITIVITY AND SPECIFICITY;
ADULT;
AGED;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
CARRIER STATE;
FEMALE;
HUMANS;
MALE;
MASS SCREENING;
MIDDLE AGED;
PATIENT SELECTION;
TUBERCULOSIS;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 34447302542
PISSN: 14620324
EISSN: 14620332
Source Type: Journal
DOI: 10.1093/rheumatology/kem064 Document Type: Letter |
|
Times cited : (38)
|
|
References (7)
|
